ライフサイエンスコーパス: anticholinergic

1 olinergic receptors in the bladder (known as anticholinergics).

2 ntipsychotics, sedative-hypnotics, or strong anticholinergics).

3 ojections, as produced by septal infusion of anticholinergics.

4 nd treatment centred on early institution of anticholinergics.

5 tilation, and receipt of benzodiazepines and anticholinergics.

6 clinical trials on cognition with other OAB anticholinergics.

7 mpared with $9.78 (95% CI, $9.16-$10.42) for anticholinergics.

8 nasal decongestant, saline douches and nasal anticholinergics.

9 Analogues of the potent anticholinergic 2-(4-phenylpiperidino)cyclohexanol (vesa

10 rected] of the patients treated with inhaled anticholinergics (2.1%) and 108 [corrected] of the contr

11 The use of anticholinergic (AC) medication is linked to cognitive i

12 In vitro enzymatic activity was assessed for anticholinergic (AChE, BuChE), anti-inflammatory (15-LOX

13 Serum anticholinergic activity (SAA), as measured by a radiore

14 iplot showed the highest correlation between anticholinergic activity and all-trans-B-cryptoxanthin,

15 is treated with medications that raise serum anticholinergic activity and are known to adversely affe

16 hors examined the relationship between serum anticholinergic activity and baseline cognitive performa

17 5% CI=-0.19, -0.05), and between serological anticholinergic activity and verbal learning (r=-0.26, 9

18 Medicines with anticholinergic activity are commonly prescribed to outp

19 This anticholinergic activity effect of A. arguta fruits can

20 Serum anticholinergic activity in schizophrenia patients shows

21 Serum anticholinergic activity showed a significant negative c

22 en studies (4,620 patients), six serological anticholinergic activity studies (382 patients), and nin

23 Serum anticholinergic activity uniquely accounted for 20% of t

24 Serum anticholinergic activity was detectable in 180 (89.6%) p

25 Serum anticholinergic activity was measured in 201 subjects wh

26 Serum anticholinergic activity was significantly associated wi

27 The most frequently prescribed drugs with anticholinergic activity were antihistamines (68.9%), ga

28 Serum anticholinergic activity, measured at study entry by rad

29 ic burden using clinical scales, serological anticholinergic activity, or tapering of anticholinergic

30 CB), the cumulative effect of medicines with anticholinergic activity, with serious adverse effects.

31 were exposed to at least one medication with anticholinergic activity.

32 tions of clozapine and NDMC as well as serum anticholinergic activity.

33 effects through a mechanism unrelated to its anticholinergic activity.

34 ruits by LC-MS-PDA-Q/TOF method and in vitro anticholinergic activity.

35 cebo but was associated with cholinergic and anticholinergic adverse events.

36 ng phase and the onset of a death rattle and anticholinergic adverse events.

37 ddition of tiotropium bromide (a long-acting anticholinergic agent approved for the treatment of chro

38 nt of patients < or =1 yr of age received an anticholinergic agent before ET intubation compared with

39 f salmeterol with those of albuterol and the anticholinergic agent ipratropium in 20 patients with st

40 Methixene hydrochloride, an anticholinergic agent, may be useful in the symptomatic

41 We explored whether the use of anticholinergic agents (ACs) affects the risk of Alzheim

42 impairment, the cautious use of selected OAB anticholinergic agents with favourable physicochemical a

43 tipsychotics, sedative-hypnotics, and strong anticholinergic agents.

44 once- or twice-daily maintenance long-acting anticholinergic and beta-agonist bronchodilators.

45 ponse and remission, and lower incidences of anticholinergic and cardiovascular side effects.

46 lations between these variables and in vitro anticholinergic and on-line antioxidant potential.

47 atients (1.9%) [corrected] receiving inhaled anticholinergics and 83 of 6661 [corrected] patients (1.

48 s between short-term cognitive safety of OAB anticholinergics and the long-term increased dementia ri

49 vention types included behavioral therapies, anticholinergics, and neuromodulation.

50 ee classes of bronchodilators-beta agonists, anticholinergics, and theophylline-are available and can

51 ren; the one exception was a small effect of anticholinergic anti-depressants being associated with b

52 took part in five drug challenges using the anticholinergic antinicotinic agent mecamylamine (MECA)

53 Inhaled anticholinergics are associated with a significantly inc

54 These studies provided good evidence that anticholinergics are effective at improving both urodyna

55 consists of medical therapy, primarily with anticholinergics as well as behavioral therapy to modify

56 response to botulinum toxin is not adequate, anticholinergics, benzodiazepines, baclofen and other me

57 dase type B inhibitors [MAOBIs], amantadine, anticholinergics, beta-blockers, or dopamine agonists) m

58 Current COPD therapy involving anticholinergics, beta2-adrenoceptor agonists and/or cor

59 ve demonstrated the benefit of a long-acting anticholinergic bronchodilator in addition to beta(2)-ag

60 Moreover, inhalation of an anticholinergic bronchodilator reduced apnea episodes in

61 a; Ba679BR) is a new-generation, long-acting anticholinergic bronchodilator that has muscarinic M(1)

62 beta-agonists, compared with ipratropium, an anticholinergic bronchodilator, and placebo in patients

63 erwise received usual care, except for other anticholinergic bronchodilators.

64 sts (LAMAs), such as tiotropium, are inhaled anticholinergic bronchodilators.

65 Existing evidence links anticholinergic burden (ACB), the cumulative effect of m

66 lity or psychiatric conditions interact with anticholinergic burden (AChB) to impact cognition and br

67 Multivariable models confirmed that higher anticholinergic burden (P = .040) and use of benzodiazep

68 24) and opiates (P = .043) along with higher anticholinergic burden (P = .066) were also associated w

69 negative correlation was identified between anticholinergic burden and global cognition (r=-0.37, 95

70 ssociation was found between recently raised anticholinergic burden and increased risk of acute cardi

71 antipsychotics and antipsychotics with high anticholinergic burden are associated with increased pne

72 ntipsychotics categorized according to their anticholinergic burden as low, medium, and high.

73 sensitivity analyses (eg, cut-off points for anticholinergic burden categories were redefined and dif

74 eceptor assay, quantifies a person's overall anticholinergic burden caused by all drugs and their met

75 iods, more patients carried higher levels of anticholinergic burden during hazard periods than during

76 The inclusion of anticholinergic burden improved association models (P <

77 Among patients with varying levels of anticholinergic burden in different periods, more patien

78 mple, 17 603 current cases had 1-2 points of anticholinergic burden in the hazard period with 0 point

79 Anticholinergic burden is associated with the cognitive

80 For each participant, anticholinergic burden levels during hazard periods (day

81 ed, 40 met inclusion criteria, comprising 25 anticholinergic burden studies (4,620 patients), six ser

82 e cognitive assessment and quantification of anticholinergic burden using clinical scales, serologica

83 Furthermore, a greater increase in anticholinergic burden was associated with a higher risk

84 , only the use of antipsychotics with a high anticholinergic burden was associated with pneumonia (AH

85 Daily anticholinergic burden was calculated for each patient b

86 The anticholinergic burden was measured for each participant

87 ween 7 medication-related metrics (including anticholinergic burden), depressive symptoms, and neuroc

88 ed and different scales were used to measure anticholinergic burden).

89 use, cognitive status, physical comorbidity, anticholinergic burden, and global health performance, c

90 When categorized by anticholinergic burden, only the use of antipsychotics w

91 comparison of 1-2 points versus 0 points of anticholinergic burden, the odds ratio was 1.86 (95% con

92 te cardiovascular events and recently raised anticholinergic burden.

93 nitive cost of medications that carry a high anticholinergic burden.

94 s improvement was negatively correlated with anticholinergic burden.

95 s and medications including corticosteroids, anticholinergics, certain antidepressants, and topiramat

96 ere rated and summed according to a modified Anticholinergic Cognitive Burden (ACB) scale.

97 exposure to prescriptions with a cumulative Anticholinergic Cognitive Burden (ACB) score of 3 or hig

98 exposure to prescriptions with a cumulative Anticholinergic Cognitive Burden (ACB) score of 3 or hig

99 nergic scores for individual drugs using the Anticholinergic Cognitive Burden Scale.

100 A approval; these are the antimuscarinic and anticholinergic/direct smooth muscle relaxant drugs.

101 It is a common perception that using an anticholinergic drug in men with bladder outlet obstruct

102 ted for each patient based on the sum of the Anticholinergic Drug Scale score for each medication adm

103 for confounding, a one-unit increase in the Anticholinergic Drug Scale score resulted in a nonsignif

104 The daily median summed Anticholinergic Drug Scale score was 2 (interquartile ra

105 lity (potentially inappropriate medications, Anticholinergic Drug Scale score).

106 nticholinergic properties, as defined by the Anticholinergic Drug Scale, does not increase the probab

107 In contrast, the anticholinergic drug trospium was transported with 11-fo

108 A promising fluconazole-synergizing anticholinergic drug, dicyclomine, increases fungal cell

109 Atropine is a clinically relevant anticholinergic drug, which blocks inhibitory effects of

110 performance in older women using a model of anticholinergic drug-induced cognitive dysfunction.

111 Anticholinergic drugs are effective in the treatment of

112 humans would be important clinically, since anticholinergic drugs are frequently used in Parkinson's

113 rmed obstruction supports the assertion that anticholinergic drugs are safe in men with bladder outle

114 Use of benzodiazepines, opiates, and anticholinergic drugs contribute to cognitive and mood d

115 mention of the possible therapeutic role of anticholinergic drugs for treating storage symptoms in s

116 Treatment of these symptoms with anticholinergic drugs has been considered hazardous in b

117 ergic systems, and central administration of anticholinergic drugs in dependent rats has been shown t

118 fects reported from its use are those of the anticholinergic drugs in general.

119 ndomized controlled trial recently evaluated anticholinergic drugs in men with lower urinary tract sy

120 Should symptoms fail to resolve, addition of anticholinergic drugs may be considered in the absence o

121 the possibility that some of the effects of anticholinergic drugs on placticity and learning may be

122 Anticholinergic drugs resolved urinary incontinence, wit

123 Although clinical guidelines recommend anticholinergic drugs to reduce the death rattle after n

124 fore the patients' regular antipsychotic and anticholinergic drugs were discontinued.

125 domains of cognition and require less use of anticholinergic drugs, which impair memory, for treatmen

126 related with use of levodopa, amantadine, or anticholinergic drugs.

127 r overactivity is traditionally treated with anticholinergic drugs.

128 e all respiratory medications except inhaled anticholinergic drugs.

129 rent autonomic failure; dramatic response to anticholinergics; early or atypical L-dopa-induced dyski

130 rease in extrapyramidal symptoms, or central anticholinergic effects were found at any olanzapine dos

131 LAMAs may have clinically meaningful central anticholinergic effects, such as increased dementia risk

132 veractive bladder detrusor muscle, including anticholinergics (eg, trospium) and beta3 agonists (eg,

133 Of 245,410 individuals, 71,569 had anticholinergic exposure (ARS 1-2, 15.6%; ARS >=3, 13.6%

134 atistically significant associations between anticholinergic exposure and cognitive performance in ch

135 rative interventional research to reduce the anticholinergic exposure in older surgical patients is l

136 Is this cohort study, higher anticholinergic exposure was associated with accelerated

137 s to measure the association of preoperative anticholinergic exposure with length of stay (LOS) and o

138 se and anxiety disorders, antidepressant and anticholinergic exposure, lifetime exposure to electroco

139 Conventional anticholinergic exposures (10-year total standardized da

140 Analyses accounting for anticholinergic exposures from both psychiatric and non-

141 Syndromes include adrenergic "fever," anticholinergic "fever," antidopaminergic "fever," serot

142 jections for overactive bladder and an adult anticholinergic for overactive bladder that underwent te

143 evidence on the effectiveness and safety of anticholinergics for male lower urinary tract symptoms.

144 esting in children; enuresis topics included anticholinergics for treating monosyptomatic enuresis re

145 eline average of 5.0 per day, was 3.4 in the anticholinergic group and 3.3 in the onabotulinumtoxinA

146 The anticholinergic group had a higher rate of dry mouth (46

147 Anticholinergics have been associated with functional de

148 nts, antidepressants, fiber, probiotics, and anticholinergics have not been adequately studied.

149 tistically significantly more effective than anticholinergics in achieving cure or improvement (high

150 Safety data from larger studies using anticholinergics in patients with overactive bladders su

151 etylcholinesterase inhibitors and muscarinic anticholinergics in these patients.

152 nd new or broadened indications for existing anticholinergics, in treating the overactive bladder in

153 QSAR) study is presented for quaternary soft anticholinergics including two distinctly different clas

154 The clinical and pharmacological anticholinergic indexes were highly correlated with each

155 ptor agonist (salbutamol) and a short-acting anticholinergic (ipratropium bromide), in COPD is encour

156 Inhaled anticholinergics (ipratropium bromide or tiotropium brom

157 ose with detrusor overactivity refractory to anticholinergics, is, however, evidenced increasingly.

158 The anticholinergic load associated with their psychiatric m

159 e in vitro and clinically derived indexes of anticholinergic load in predicting these cognitive impai

160 es show utility in predicting the effects of anticholinergic load on cognition in schizophrenia.

161 edications were quantified using the CRIDECO Anticholinergic Load Scale.

162 Anticholinergic load was associated with lower scores on

163 lly evaluation of various inhaled therapies (anticholinergics, long-acting beta-agonists, and cortico

164 ation inhaled therapies (long-acting inhaled anticholinergics, long-acting inhaled beta-agonists, or

165 antihistamines, metoclopramide, domperidone, anticholinergics, loop diuretics, urologics, and ophthal

166 ill a prescription for a beta3-agonist vs an anticholinergic medication (adjusted odds ratio, 0.46; 9

167 e who were not receiving inhaled long-acting anticholinergic medication (difference in composite at 5

168 cipants were randomly assigned to daily oral anticholinergic medication (solifenacin, 5 mg initially,

169 idol-treated subjects to require concomitant anticholinergic medication after 4 weeks (20% versus 63%

170 studies quantifying the relationship between anticholinergic medication and cognitive function in psy

171 deling to determine the relationship between anticholinergic medication burden and cognition.

172 Anticholinergic medication burden from all medication cl

173 Anticholinergic medication burden in schizophrenia is su

174 pact of cognitive impairment attributable to anticholinergic medication burden may help optimize cogn

175 ars after initial studies suggested that the anticholinergic medication class could affect memory.

176 Anticholinergic medication exposure was quantified using

177 Finally, tapering off anticholinergic medication improved the scores in verbal

178 , have potential implications for the use of anticholinergic medication in elderly Parkinson's diseas

179 s on recent data determining the efficacy of anticholinergic medication in men with lower urinary tra

180 Efficacy and safety studies of anticholinergic medication in men with lower urinary tra

181 From a clinical perspective, tapering off anticholinergic medication in patients with psychosis ma

182 nd meta-analysis on the associations between anticholinergic medication use and cognitive performance

183 he ICU is frequent, the relationship between anticholinergic medication use and delirium in this sett

184 e relative to the presence versus absence of anticholinergic medication(s) in children.

185 garding the role of invasive urodynamics and anticholinergic medication, and further large-scale pros

186 r adjusted analyses included increasing age, anticholinergic medication, history of urinary retention

187 asthma and those not receiving a long-acting anticholinergic medication, newly prescribed LABA and in

188 use of antihypertensive, lipid-lowering, or anticholinergic medication; and apolipoprotein E genotyp

189 NS-active medications (54.32% vs 48.39%) and anticholinergic medications (17.79% vs 15.96%) and less

190 lso had a modestly greater decline in use of anticholinergic medications (quarterly change in use, -0

191 d studies that investigated whether reducing anticholinergic medications affects cognitive function i

192 howed associations between several different anticholinergic medications and dementia.

193 efficacy of neuromodulator injections, oral anticholinergic medications and laser therapy.

194 Anticholinergic medications and onabotulinumtoxinA are u

195 Increased anticholinergic medications and prior dementia, in which

196 Anticholinergic medications are associated with adverse

197 s the key neurochemical impairment in PD and anticholinergic medications are used for symptomatic tre

198 re likely to discontinue cardiometabolic and anticholinergic medications compared with the control gr

199 Anticholinergic medications do not appear to be associat

200 ich is reflected in an increased efficacy of anticholinergic medications during acute asthma attacks.

201 Cognitive side effects of anticholinergic medications in older adults are well doc

202 Ingestion of anticholinergic medications is common in pediatrics.

203 These findings suggest that minimizing anticholinergic medications is important for healthy agi

204 Anticholinergic medications such as ipratropium improve

205 s are most affected by the administration of anticholinergic medications to patients with schizophren

206 Anticholinergic medications to treat overactive bladder

207 gonists working alone or in conjunction with anticholinergic medications will improve clinical sympto

208 nonsurgical populations; the association of anticholinergic medications with outcomes in elective su

209 ion VA drug classes, took 0.6 +/- 0.8 strong anticholinergic medications, and had 3.9 +/- 2.6 teeth r

210 U medications, especially some sedatives and anticholinergic medications, and keeping patients more a

211 nd oxybutynin treatment, a new generation of anticholinergic medications, such as tolterodine, has be

212 cal anticholinergic activity, or tapering of anticholinergic medications.

213 ic, central nervous system (CNS)-active, and anticholinergic medications.

214 for managing urge urinary incontinence with anticholinergic medications.

215 xerostomia in elderly persons is the use of anticholinergic medications.

216 acting anticholinergics (n = 7), long-acting anticholinergics (n = 10), long-acting beta2-agonists (n

217 CTs examined inhaled therapies: short-acting anticholinergics (n = 7), long-acting anticholinergics (

218 pain control, minimizing benzodiazepines and anticholinergics, normalizing the sleep-wake cycle, prov

219 tcomes were receipt of a beta3-agonist or an anticholinergic OAB medication.

220 beta3-agonist prescription compared with an anticholinergic OAB prescription.

221 tention, because of the inhibitory effect of anticholinergics on bladder contraction in the presence

222 Given that anticholinergics only decrease mucus production, it is u

223 cally significant associations found between anticholinergic or antihistamines and poor performance.

224 lowing attention to fluid intake relies upon anticholinergic or beta3-adrenergic agonist treatment wi

225 Pharmacologic interventions include use of anticholinergics or antipsychotic medications for dement

226 monotherapy using either long-acting inhaled anticholinergics or long-acting inhaled beta-agonists fo

227 ulation, high-risk ingestion, coingestion of anticholinergics or opioids, age younger than 6 years, p

228 g inhaled beta-agonists, long-acting inhaled anticholinergics, or inhaled corticosteroids.

229 However, trials involving anticholinergics other than oxybutynin have not shown su

230 n the proper clinical situation such as pure anticholinergic overdose with severe symptoms, physostig

231 demonstrated that the administration of the anticholinergic oxybutynin leads to impaired memory and

232 een shown to be useful in cases of confirmed anticholinergic poisoning by controlling agitation and r

233 Physostigmine, an antidote for anticholinergic poisoning, could be useful in this situa

234 yperthermia, neuroleptic malignant syndrome, anticholinergic poisoning, sympathomimetic poisoning, an

235 Anticholinergic-polygenic interactions significantly imp

236 ically useful standard index of the relative anticholinergic potency of psychiatric medications; 2) t

237 , paroxetine has approximately one-fifth the anticholinergic potential of nortriptyline in older pati

238 l of 2 229 297 individuals (75.0%) filled an anticholinergic prescription, and 590 255 (19.9%) filled

239 f treatment with antihypertensive drugs with anticholinergic properties (AC AHT) on the risk of vascu

240 and 24% were on 1 or more Drugs with Strong Anticholinergic Properties (DSAPs) at initial visits.

241 Drugs with strong anticholinergic properties are used under a variety of c

242 ase delirium risk and use of medication with anticholinergic properties in the ICU is frequent, the r

243 stigated whether exposure to medication with anticholinergic properties increases the probability of

244 Exposure to medication with anticholinergic properties, as defined by the Anticholin

245 Meclizine, an antihistamine with anticholinergic properties, is the most used antiemetic

246 When prescribing multiple medicines with anticholinergic properties, physicians need to be cautio

247 used to treat schizophrenia have significant anticholinergic properties, which are linked to cognitiv

248 ducts rich in flavonols and carotenoids with anticholinergic properties.

249 T3 receptor antagonists, antihistamines, and anticholinergics reduce the incidence of PONV, whereas m

250 Anticholinergics remain the first line in pharmacotherap

251 Yet, anticholinergics remain the predominant OAB medication p

252 medication exposure was quantified using the Anticholinergic Risk Scale (ARS).

253 Short-acting anticholinergic (SAAC) should be added to SABA for older

254 asured for each participant by adding up the anticholinergic scores for individual drugs using the An

255 with high Drug Burden Index (DBI-cumulative anticholinergic/sedative exposure) affected behaviors ov

256 Its lack of both anticholinergic side effects and interference with the m

257 cal index, based on clinician ratings of the anticholinergic side effects of medications.

258 types presents the potential for undesirable anticholinergic side effects.

259 components of the primary end point, inhaled anticholinergics significantly increased the risk of MI

260 Inhaled anticholinergics such as ipratropium bromide (IB), when

261 hmia, and occurs when used in the absence of anticholinergic symptoms.

262 therapy with inhaled beta-agonists, inhaled anticholinergics, systemic corticosteroids, and intraven

263 Oral anticholinergic therapy and onabotulinumtoxinA by inject

264 an increase in postvoid residual volume with anticholinergic therapy.

265 nists salmeterol and formeterol, and the new anticholinergic tiotropium bromide provide a better ther

266 This paper reviews the anticholinergic toxidrome and pathophysiology, recent li

267 patients and the potential visual effects of anticholinergic treatments for ocular diseases.

268 lection when rats were tested off-drug, both anticholinergic treatments were effective in disrupting

269 ), phosphodiesterase inhibitors (tadalafil), anticholinergics (trospium), and beta3 agonists (mirabeg

270 rates in gait speed or grip strength between anticholinergic TSDD and mSDD categories and per unit in

271 Anticholinergic use, extrapyramidal symptoms, and estima

272 MI, or stroke (2.9% of patients treated with anticholinergics vs 1.8% of the control patients; RR, 1.